the bar inches a little higher

Recent trial results in renal cell cancer have revealed a significant survivl benefit from Nexavar. Doesnt look so much to me and the need for Coramsine, if it can repeat the results from the previous trial, is still IMHO as urgent as ever.

"The trial involved a total of 903 patients, and 48% of the placebo group ultimately crossed over to sorafenib. Sixteen months after crossover, the final analysis of overall survival showed median survival of 17.8 months with sorafenib versus 15.2 months with placebo, which translated into a nonsignificant 12% improvement.

The pre-planned secondary analysis of overall survival censored placebo patients at crossover. Median survival in the placebo group decreased to 14.3 months, resulting in a statistically significant 22% difference favoring sorafenib (p=.0287)."
http://neuro_healthcentersonline.mediwire.com/main/Default.aspx?P=Content&ArticleID=460662